Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study.

By J. Bonneterre, B. Thürlimann, J. Robertson, M. Krzakowski, L. Mauriac, P. Koralewski, I. Vergote, A. Webster, M. Steinberg, M. V. Euler. Journal of Clinical Oncology, 2000

868 citations recorded by the source corpus.

Subfields: Cancer Research, Genetics

View Paper: https://www.semanticscholar.org/paper/306a4fa5a6d62d577dca44dacd424e1d609771af

Citations in the corpus

• ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2) (2014, neutral): “500 mg, every 4 weeks) [77–88].”